WO2004040302A8 - ＲＡＰＬ・Ｒａｐ１相互作用制御 - Google Patents

ＲＡＰＬ・Ｒａｐ１相互作用制御

Info

Publication number
WO2004040302A8
WO2004040302A8 PCT/JP2003/013937 JP0313937W WO2004040302A8 WO 2004040302 A8 WO2004040302 A8 WO 2004040302A8 JP 0313937 W JP0313937 W JP 0313937W WO 2004040302 A8 WO2004040302 A8 WO 2004040302A8
Authority
WO
WIPO (PCT)
Prior art keywords
rap1
immunity
regulation
integrin adhesion
allergy
Prior art date
Application number
PCT/JP2003/013937
Other languages
English (en)
French (fr)
Other versions
WO2004040302A1 (ja
Inventor
Tatsuo Kinashi
Hiroshi Shikama
Original Assignee
Ishihara Sangyo Kaisha
Tatsuo Kinashi
Hiroshi Shikama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ishihara Sangyo Kaisha, Tatsuo Kinashi, Hiroshi Shikama filed Critical Ishihara Sangyo Kaisha
Priority to AU2003277537A priority Critical patent/AU2003277537A1/en
Priority to EP03809869A priority patent/EP1557670A4/en
Priority to US10/532,683 priority patent/US20070031415A1/en
Publication of WO2004040302A1 publication Critical patent/WO2004040302A1/ja
Publication of WO2004040302A8 publication Critical patent/WO2004040302A8/ja

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

インテグリン接着制御分子としてのRap1の機能破綻は免疫病である炎症、アレルギー、自己免疫疾患、癌免疫、移植免疫等の病態と密接に関連していると考えられるが、Rap1によるインテグリン接着制御のメカニズムを解明することはこれらの免疫病の病態理解や治療法を開発することにつながる。Rap1によるインテグリン接着性制御に関与する分子として、p30が同定されてきているが、該p30はRap1と結合して、その機能を制御していることが見出された。この知見を利用することにより、p30とRap1との結合阻害剤などが開発でき、炎症、アレルギー、自己免疫疾患、癌免疫、移植免疫等の治療薬の開発、さらには制御機構の解明が可能となる。
PCT/JP2003/013937 2002-10-30 2003-10-30 ＲＡＰＬ・Ｒａｐ１相互作用制御 WO2004040302A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003277537A AU2003277537A1 (en) 2002-10-30 2003-10-30 REGULATION OF INTERACTION BETWEEN RAPL AND Rap1
EP03809869A EP1557670A4 (en) 2002-10-30 2003-10-30 REGULATION OF INTERACTIONS BETWEEN RAPL AND RAP1
US10/532,683 US20070031415A1 (en) 2002-10-30 2003-10-30 Regulation of interaction between rapl and rap1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002-316892 2002-10-30
JP2002316892 2002-10-30

Publications (2)

Publication Number Publication Date
WO2004040302A1 WO2004040302A1 (ja) 2004-05-13
WO2004040302A8 true WO2004040302A8 (ja) 2005-03-24

Family

ID=32211702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/013937 WO2004040302A1 (ja) 2002-10-30 2003-10-30 ＲＡＰＬ・Ｒａｐ１相互作用制御

Country Status (4)

Country Link
US (1) US20070031415A1 (ja)
EP (1) EP1557670A4 (ja)
AU (1) AU2003277537A1 (ja)
WO (1) WO2004040302A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8425662B2 (en) 2010-04-02 2013-04-23 Battelle Memorial Institute Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies
WO2014050908A1 (ja) * 2012-09-26 2014-04-03 富士フイルム株式会社 ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物
KR102433569B1 (ko) * 2015-01-29 2022-08-18 타운즈 컴퍼니 리미티드 마이코플라즈마 뉴모니아의 면역학적 검출법 및 키트
WO2016121832A1 (ja) * 2015-01-29 2016-08-04 株式会社ビーエル マイコプラズマ・ニューモニエの免疫学的検出法およびキット

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02231500A (ja) * 1988-05-31 1990-09-13 Mitsubishi Kasei Corp 新規なｇｔｐ結合蛋白質及びその産生方法
JPH0284181A (ja) * 1988-09-20 1990-03-26 Rikagaku Kenkyusho 癌抑制遺伝子、その単離法、それがコードするペプチド、及び抗体
US5175383A (en) * 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
ZA915023B (en) * 1990-07-10 1992-05-27 Ishihara Sangyo Kaisha Diaminotrifluoromethylpyridine derivatives,process for their production and phospholipase a2 inhibitor containing them
DE69127595T2 (de) * 1990-07-10 1998-01-22 Ishihara Sangyo Kaisha Diaminotrifluoromethylpyrimidinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Phospholipase-A2-Inhibitoren
JPH06135934A (ja) * 1991-12-27 1994-05-17 Ishihara Sangyo Kaisha Ltd ピリジン誘導体又はその塩を含有するホスホリパーゼ▲ａ２▼阻害剤、抗炎症剤又は抗膵炎剤
US5767337A (en) * 1995-07-31 1998-06-16 Duke University Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice
ZA981430B (en) * 1997-02-28 1998-08-24 Ishihara Sangyo Kaisha Anticancer composition
US6140488A (en) * 1997-10-01 2000-10-31 Zhang; Xian-Feng Ras-binding protein (PRE1)
US6485910B1 (en) * 1998-02-09 2002-11-26 Incyte Genomics, Inc. Ras association domain containing protein
CA2350415A1 (en) * 1998-11-18 2000-05-25 Incyte Pharmaceuticals, Inc. Inflammation-associated genes
TWI283578B (en) * 2000-01-31 2007-07-11 Ishihara Sangyo Kaisha Therapeutic agent for alimentary disease comprising diaminotrifluoromethylpyridine derivative
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
US6596488B2 (en) * 2000-03-30 2003-07-22 City Of Hope Tumor suppressor gene
US20030144196A1 (en) * 2001-08-21 2003-07-31 Bowen Michael A. Activated T lymphocyte nucleic acid sequences and polypeptides encoded by same
WO2003052380A2 (en) * 2001-12-14 2003-06-26 The General Hospital Corporation Recruitment of mst1 or mst2 protein kinase to induce apoptosis in eukaryotic cells

Also Published As

Publication number Publication date
EP1557670A4 (en) 2007-03-07
US20070031415A1 (en) 2007-02-08
EP1557670A1 (en) 2005-07-27
WO2004040302A1 (ja) 2004-05-13
AU2003277537A1 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
WO2004067568A3 (en) Human il-1 beta antagonists
WO2005014650A3 (en) Antibodies specific for sclerostin and methods for increasing bone mineralization
WO2005047545A3 (en) Microarray controls
SG147444A1 (en) Anti-ox40l antibodies
WO2006110525A3 (en) Authorization techniques
WO2006084264A3 (en) Cd20 antibody variants and uses thereof
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
GEP20115195B (en) Antibodies directed against amyloid-beta peptide and use thereof
EA200700210A1 (ru) ВАРИАНТЫ ОБЛАСТИ Fc
NZ611859A (en) Antibody purification
WO2007114969A3 (en) Hinge bracket for a pocket door
BRPI0517973A (pt) método para purificar o fsh
WO2009048537A3 (en) Humanized antibody
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
AU2002364954A1 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
CY1112673T1 (el) Φαινοξυ αιθερες αμινοξεων
WO2005023302A3 (en) Anti-cd20 therapy of ocular disorders
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
AUPS300902A0 (en) Decoupling mechanism for hydraulic pump/motor assembly
WO2004040302A8 (ja) ＲＡＰＬ・Ｒａｐ１相互作用制御
WO2004046188A3 (en) Anti-activated ras antibodies
WO2006024958A3 (en) Cannabinoid compositions and methods of use thereof
AU2003211877A1 (en) Remedies for sex hormone-dependent disease
WO2004029214A3 (en) Lfa-1 alpha subunit antibodies and methods of use
WO2003066097A3 (en) A novel target to inhibit angiogenesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2003809869

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007031415

Country of ref document: US

Ref document number: 10532683

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003809869

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10532683

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003809869

Country of ref document: EP